Efficacy of Madhav Rasayan Plus as adjuvant in moderate COVID-19 patients: Preliminary outcomes of randomized controlled trial

Efficacy of Madhav Rasayan Plus as adjuvant in moderate COVID-19 patients: Preliminary outcomes of randomized controlled trial

Apart from all the gloominess, the COVID-19 Pandemic has a silver lining of bringing a renaissance as Ayurveda and integrated medicine are becoming a choice for acute as well as infective diseases. Here we report outcomes of a preliminary work, the randomized controlled trial (CTRI/2021/02/031256) o...

Cijeli opis

Bibliografski detalji
Glavni autori: Sameer Jamadagni, Prasad Pandkar, Tushar Saundankar, Girish Shirke, Shailesh Malekar, V.G. Vaidya
Format: Članak
Jezik:English
Izdano: Elsevier 2022-07-01
Serija:Journal of Ayurveda and Integrative Medicine
Teme:
Ayurveda
COVID-19
Madhav rasayan plus
Clinical trial
Integrative medicine
Online pristup:http://www.sciencedirect.com/science/article/pii/S0975947622000493

Internet

http://www.sciencedirect.com/science/article/pii/S0975947622000493

Slični predmeti